• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » House probes why medical devices take longer to hit U.S. market

House probes why medical devices take longer to hit U.S. market

February 16, 2011 By MassDevice staff

Rep. Joe Pitts

The medical device industry’ s increased juice in Washington is starting to power the Beltway agenda, as Republican House leaders take note of differences between European regulatory bodies and those in the U.S. Can Congressional hearings be far behind?

Rep. Joe Pitts (R-Pa.), the newly installed chairman of the House Energy and Commerce Health Subcommittee, signaled his intention to probe recent buzz that the European regulatory pipeline moves faster than its equivalent at the Food & Drug Administration. Throwing in his two cents in an op-ed in the The Hill yesterday, Pitts said he’s so interested in the issue that he’s looking to use his new power to get some answers.

“This week, the House of Representatives issued direction to the various committees to investigate federal government rules affect on jobs and the economy,” he wrote. “The Energy and Commerce Health Subcommittee has oversight over the FDA and, as chairman, I want us to explore why Europe has gained such a significant advantage over American companies.”

Pitts’ call for further investigation is a sure sign that the medical device industry’s public relations campaign is getting traction with its intended audience — Republican lawmakers riding the mid-term election wave.

Med-tech has pushed hard, looking to draw attention to three recent studies by PricewaterhouseCoopers, Stanford University and the Boston Consulting Group which conclude that medical innovation in the U.S. is sagging from over-regulation.

If successful, the PR blitz could undermine the federal watchdog agency’s call for stricter 510(k) regulations and even put a wrinkle in the re-authorization of the Medical Device User Fee Act set for 2012. Getting Pitts to parrot some favorite talking points is one sign that the message is sticking.

“Unfortunately, the FDA has become risk-averse in recent years,” he wrote. “Approval times have crept up, nearly doubling the time required in some cases. This means that European patients are receiving access to devices two years before American patients. In some cases, devices approved in Europe have never been legal in the U.S.”

Filed Under: Food & Drug Administration (FDA), Healthcare Reform, News Well

More recent news

  • A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology
  • Dexcom continues advances in AI for CGM, type 2 diabetes awareness
  • Tandem continues to deliver more options, benefits for those with diabetes
  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy